Core Viewpoint - BioAge Labs, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its initial public offering and subsequent announcement regarding the discontinuation of a clinical trial for its lead product candidate, azelaprag [2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased BioAge stock linked to its IPO on September 26, 2024 [2]. - The complaint states that on December 6, 2024, BioAge announced the discontinuation of the STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in stock price from $20.09 to $4.65 per share within a day [3]. Group 2: Investor Information - Investors affected by the situation have until March 10, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Lawsuit - BIOA